[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342341-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342341-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","vertical-inhibition-of-p110akt-and-n-cadherin-enhances-treatment-efficacy-in-pik3ca-aberrated-ovarian-cancer-cells","Vertical inhibition of p110α/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells","","PIK3CA (encoding PI3Kα/p110α) is frequently altered in human cancers, while its point mutations are rare in serous ovarian cancer despite common PIK3CA amplification. This study compares functional impacts of PIK3CA amplification versus the E545K driver mutation and shows both generate tumorigenic phenotypes. AKT signaling activates broadly, but ERK1/2 induction occurs selectively with E545K. AKT increases YAP1 Ser127 phosphorylation, raises cytoplasmic YAP, and promotes migration via RAC1 activation, while also upregulating N-cadherin.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/vertical-inhibition-of-p110akt-and-n-cadherin-enhances-treatment-efficacy-in-pik3ca-aberrated-ovarian-cancer-cells/342341/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/vertical-inhibition-of-p110akt-and-n-cadherin-enhances-treatment-efficacy-in-pik3ca-aberrated-ovarian-cancer-cells/342341.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address about PIK3CA alterations in serous ovarian cancer?","Question",{"text":63,"@type":64},"It addresses whether PIK3CA amplification and PIK3CA driver mutations have the same functional impact, since amplification is frequent while point mutations are rare in the serous subtype.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does AKT signaling differ between E545K and PIK3CA amplification models?",{"text":68,"@type":64},"AKT signaling is activated in both E545K knock-in and PIK3CA-overexpressing cells, but the ERK1/2 pathway is induced selectively by E545K, not by PIK3CA amplification.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do YAP1 and N-cadherin play in migration and therapeutic targeting?",{"text":72,"@type":64},"AKT increases YAP1 Ser127 phosphorylation, leading to higher cytoplasmic YAP and enhanced migration through RAC1 activation; AKT also upregulates N-cadherin, and inhibiting N-cadherin reduces migration, with additive effects when co-targeting N-cadherin and p110a/AKT.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342341,1790176345,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Vertical inhibition of p110a/AKT and N-cadherin enhances treatment efﬁcacy in PIK3CA-aberrated ovarian  \ncancer cells  \nShibo Zhang 1,2, Hei Ip Hong 1, Victor C. Y. Mak 1, Yuan Zhou 1, Yiling Lu3, Guanglei Zhuang4,5 and Lydia W. T. Cheung 1   \n1 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China  \n2 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China  \n3 Division of Cancer Medicine, Department of Genomic Medicine, UT MD Anderson Cancer Centre, Houston, TX, USA  \n4 State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, China  \n5 Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, China  \nKeywords  \ncytoplasmic YAP; N-cadherin; p110a; PI3K; PIK3CA; serous ovarian cancer  \nCorrespondence  \nL. W. T. Cheung, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L1-44, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, China  \nE-mail: lydiacwt@hku. hk  \n(Received 22 March 2024, revised 14 August 2024, accepted 28 October 2024, available online 15 November 2024)  \ndoi:10 . 1002/1878-0261 .13761  \nPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [PIK3CA, encoding PI3Kalpha (also known as p110a)] is one of the most commonly aberrated genes in human cancers. In serous ovarian cancer, PIK3CA ampliﬁcation is highly frequent but PIK3CA point mutation is rare. However, whether PIK3CA ampliﬁcation and PIK3CA driver mutations have the same functional impact in the disease is unclear. Here, wereport that both PIK3CA ampliﬁcation and E545K mutation are tumorigenic. While the protein kinase B (AKT) signaling axis was activated in both E545K knock-in cells and PIK3CA-overexpressing cells, the mitogen-activated protein kinase 3/1 (ERK1/2) pathway was induced selectively by E545K mutation but not PIK3CA ampliﬁcation. Intriguingly, AKT signaling in these PIK3CA-aberrated cells increased transcriptional coactivator YAP1 (YAP) Ser127 phosphorylation and thereby cytoplasmic YAP levels, which in turn increased cell migration through Ras-related C3 botulinum toxin substrate 1 (RAC1) activation. In addition to the altered YAP signaling, AKT upregulated N-cadherin expression, which also contributed to cell migration. Pharmacological inhibition of N-cadherin reduced cell migratory potential. Importantly, co-targeting N-cadherin and p110a/AKT caused additive reduction in cell migration in vitro and metastases formation in vivo. Together, this study reveals the molecular pathways driven by the PIK3CA aberrations and the exploitable vulnerabilities in PIK3CA-aberrated serous ovarian cancer cells.  \nAbbreviations  \nAKT, protein kinase B; CI, conﬁdence interval; DEGs, differentially expressed genes; DEPs, differentially expressed proteins; GO, gene ontology; GSEA, gene set enrichment analysis; HDR, homology directed repair; HNSCC, head and neck squamous carcinoma; HR, hazard ratio; HRP, horseradish peroxidase; IHC, immunohistochemistry; IRS, immunoreactive score; KEGG, Kyoto Encyclopedia of Genes and Genomes; KM, Kaplan–Meier; MAPK, mitogen-activated protein kinase; NES, normalized enrichment score; PAM, protospacer adjacent motif; PI3K, phosphoinositide-3 kinase; RAC1, Ras-related C3 botulinum toxin substrate 1; RNA-seq, RNA sequencing; RPPA, reverse phase protein array; TCGA, The Cancer Genome Atlas.  \n1132 Molecular Oncology 19 (2025) 1132–1154 ª 2024 The Author(s) . Molecular Oncology published by John Wiley & Sons Ltd on behalf of  \nFederation of European Biochemical Societies.  \nThis is an open access article under the terms of the Creative Commons Attribution License, whic","cbCaigdj8GkIgBiA","https://ap.wps.com/l/cbCaigdj8GkIgBiA","pdf",4889146,23,"English","# Introduction\n## p110α and PI3K signaling fundamentals\n## PIK3CA hotspots and prevalence across cancers\n## PIK3CA amplification versus mutation in ovarian cancer","[{\"question\":\"What problem does the study address about PIK3CA alterations in serous ovarian cancer?\",\"answer\":\"It addresses whether PIK3CA amplification and PIK3CA driver mutations have the same functional impact, since amplification is frequent while point mutations are rare in the serous subtype.\"},{\"question\":\"How does AKT signaling differ between E545K and PIK3CA amplification models?\",\"answer\":\"AKT signaling is activated in both E545K knock-in and PIK3CA-overexpressing cells, but the ERK1/2 pathway is induced selectively by E545K, not by PIK3CA amplification.\"},{\"question\":\"What role do YAP1 and N-cadherin play in migration and therapeutic targeting?\",\"answer\":\"AKT increases YAP1 Ser127 phosphorylation, leading to higher cytoplasmic YAP and enhanced migration through RAC1 activation; AKT also upregulates N-cadherin, and inhibiting N-cadherin reduces migration, with additive effects when co-targeting N-cadherin and p110a/AKT.\"}]","Vertical inhibition of p110α/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells | PDF",1790046222,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6572629ba00723a48d99df368c17cc11.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62ce1d47923b230bac5a2b974f25d452.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52ddda699555d78bafe49221fef16a03.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d7c66069ceeb07212365b3843e0cf1e.webp",980,1287]